Label Battles: Beovu And Eylea Contest Begins In AMD
Novartis's injectable anti-VEGF Beovu was approved for wet AMD by the US FDA
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
